Can we count your visit with Google Analytics? No ads, no profiles. Details
ARDX
NASDAQAnalystsStrong Buy10+344%Health Care · Biotechnology
Each weekday: the watchlist of pullbacks inside uptrends, every new ticker teardown, and the bubble shifts that move names like this one. Free. Education, not advice.
Free when you join: the $HOOD Teardown Dossier (Robinhood Markets), the full desk file we sell in the shop. One per new reader.
No spam. One email per day max, unsubscribe in one click. Pro ($49/mo) includes every dossier and report in the shop.
Structural: dual commercial franchises on a single molecule (tenapanor) targeting large IBS-C and CKD dialysis markets; Medicare 2025 reimbursement for XPHOZAH removes the key payer overhang that suppressed the stock in 2023-2024.
XPHOZAH dialysis penetration still early (<10% of ~550k US dialysis patients); IBS-C market underpenetrated vs. Linzess/Trulance; operating leverage as SG&A scales sub-linearly; partnership optionality with Kyowa Kirin for Japan XPHOZAH rights.
dialysis formulary adoption slower than modeled (DaVita/Fresenius P&T cycles); generic tenapanor IP risk post-2033; cash burn if ramp lags; competitive pressure from Auryxia and phosphate binders in CKD.
It reads our $ARDX data (thesis, key levels, peers, a year of prices) and any chart screenshot you paste, then explains the setup in plain English. Free with an email login, 5 questions a day. Education only: it never tells you to buy or sell, and it can be wrong, so check the numbers.
High-signal only
Auto-computed retracement of the trailing 52w low-high leg. Recomputed on each refresh; not a curated level.